A Randomized, Open-Label, Active-Controlled, Phase II Study of Intravenous Anetumab Ravtansine (BAY 94-9343) or Vinorelbine in Patients with Advanced or Metastatic Malignant Pleural Mesothelioma Overexpressing Mesothelin and Progressing on First Line Platinum/Pemetrexed-Based Chemotherapy
The primary objective of this study is to: Test the superiority of anetumab ravtansine monotherapy over vinorelbine in progression-free survival (PFS) The secondary objectives of this study are to: Test overall survival (OS) Evaluate pulmonary function Evaluate patient-reported outcomes (PROs) symptom burden and health-related quality of life (QoL) Evaluate other indicators of treatment efficacy (indicators of tumor response) Evaluate safety
Study Number: 

PH 276715

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.